The 12-month price targets, analyzed by analysts, offer insights with an average target of $58.25, a high estimate of $63.00, and a low estimate of $41.00. Experiencing a 6.49% decline, the current ...

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh ...

Analysts' ratings for Arcturus Therapeutics (NASDAQ:ARCT) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ...